Disease/Infection News

RSS

Recombinant attenuated Salmonella vaccines hold promise against infectious diseases

A powerful new class of therapeutics, known as recombinant attenuated Salmonella vaccines (RASV), holds great potential in the fight against fatal diseases including hepatitis B, tuberculosis, cholera, typhoid fever, AIDS and pneumonia.

30 Jun 2011

Physicians urge FDA not to approve Truvada as an HIV prevention pill

Last week, a group of 55 U.S. physicians sent a letter to the U.S. Food & Drug Administration (FDA), urging the agency not to approve the use of Gilead's HIV/AIDS treatment drug Truvada for use as an HIV prevention pill - also known as "pre-exposure prophylaxis" (PrEP).

30 Jun 2011

Rapid, accurate test differentiates between bacterial and viral infections

Scientists are reporting development and successful testing of a rapid and accurate test to tell the difference between bacterial and viral infections. Those common afflictions often have similar symptoms but vastly different treatments - antibiotics work for bacterial infections but not for viruses. The report appears in ACS' journal Analytical Chemistry.

30 Jun 2011

Queensland authorities try to contain Hendra virus outbreak

The Queensland authorities have stepped up their efforts to contain an outbreak of the deadly Hendra virus on a farm near Beaudesert, south of Brisbane.

29 Jun 2011

Nurses drive quality initiative, save lives and money

Nurses on a surgical intensive care unit (SICU) at a large academic medical center cut bloodstream infections to zero and saved more than $200,000 during a six-month period.

29 Jun 2011

GAO reports on government response to H1N1 pandemic

GAO on Monday published two reports on the government's response to the 2009 H1N1 influenza pandemic.

29 Jun 2011

Gene PNPLA3 offers potential therapeutic target in chronic hepatitis C liver damage

New research confirms that a variant on the patatin-like phospholipase-3 (PNPLA3) gene increases risk of steatosis and fibrosis progression in patients with chronic hepatitis C virus (HCV). The PNPLA3 single nucleotide polymorphism (SNP) rs 738409 may represent an important genetic predictor and potential therapeutic target in chronic HCV liver damage.

29 Jun 2011

France 24's Health program examines challenges to fighting malaria in Madagascar

France 24's video program Health examines challenges to fighting malaria in Madagascar, where some people who cannot afford newer artemisinin-based combination therapies use older, less-effective medications that can promote drug resistance and others misuse mosquito nets.

29 Jun 2011

Anacor, DNDi and SCYNEXIS complete SCYX-7158 pre-clinical studies for combating sleeping sickness

Anacor Pharmaceuticals, the Drugs for Neglected Diseases initiative (DNDi), and SCYNEXIS Inc. today announced the successful completion of pre-clinical studies for the first new oral drug candidate discovered specifically to combat human African trypanosomiasis (HAT), also known as sleeping sickness.

29 Jun 2011

Prototype small molecule drugs could suppress hepatitis C

Targeted multi-drug treatments for hepatitis C patients that could stop the virus in its tracks have come a step closer, thanks to researchers at the University of Leeds, UK.

29 Jun 2011

Voluntary medical male circumcision is a cost-effective, safe way to prevent HIV

Emmanuel Njeuhmeli, a senior biomedical prevention advisor in the USAID Office of HIV/AIDS, discusses efforts to raise awareness about male circumcision as a "cost saving and effective form of HIV prevention" in a post on USAID's "Impact Blog."

29 Jun 2011

Combination therapies inhibiting P7 could prevent spread of HCV

British researchers have identified specific resistance mutations for two classes of p7 inhibitor, which may explain their lack of effectiveness in clinical trials combined with current standard of care.

29 Jun 2011

Cotton swab dramatically reduces infections in post-operative incision sites

A simple item found in almost every medicine cabinet - a cotton swab -- may be a key tool in the fight against post-surgical wound infections.

29 Jun 2011

Bristol-Myers Squibb and Mylan expand access to HIV drug Reyataz in sub-Saharan Africa and India

Bristol-Myers Squibb Company today announced a new agreement to expand access to Reyataz (atazanavir sulfate). The immunity-from-suit agreement signed with Matrix Laboratories Limited, a Mylan Company, enables the generic company to manufacture and sell atazanavir, as well as stavudine and didanosine, in sub-Saharan Africa and India.

29 Jun 2011

Infection rate drops at Nebraska hospital after initiating new protocols

Nurses, occupational and physical therapists, case managers and education staff, all working together at a 300-bed Nebraska rehabilitation hospital, have successfully implemented a team approach to dramatically reduce infections from urinary catheters, the most prevalent type of infection acquired in healthcare settings.

28 Jun 2011

Tibotec, Gilead Sciences enter license agreement for new combination product of PREZISTA and cobicistat

Tibotec Pharmaceuticals today announced that it has entered into a license agreement with Gilead Sciences, Inc., for the development and commercialization of a new once-daily single tablet fixed-dose antiretroviral combination product containing Tibotec's protease inhibitor PREZISTA® (darunavir) and Gilead's cobicistat, an investigational pharmacoenhancing or "boosting" agent.

28 Jun 2011